Commercial Science Activities

The following arrangements have been reviewed and approved by the Johns Hopkins University in accordance with its conflict-of-interest policies

Prof. Gray is an unpaid board member (director) of the Rosetta Commons, a consortium of academic and non-profit laboratories. Under institutional participation agreements between the University of Washington, acting on behalf of the Rosetta Commons, Johns Hopkins University may be entitled to a portion of revenue received on licensing Rosetta software. More information on our lab’s relationship to Rosetta is available here.

Prof. Gray has a fiduciary role in Levitate Bio LLC, which is owned by the Rosetta Commons Foundation. Levitate Bio LLC has a non-exclusive license to distribute the Rosetta software, which includes methods developed in our lab. Under institutional participation agreements between the University of Washington, acting on behalf of the Rosetta Commons, Johns Hopkins University may be entitled to a portion of revenue received on licensing Rosetta software.

Prof. Gray has a financial interest in Cyrus Biotechnology. Cyrus Biotechnology Inc. licenses Rosetta and PyRosetta software from University of Washington, acting on behalf of the Rosetta Commons and Johns Hopkins University. Up through May 2024, Cyrus had a non-exclusive license to distribute the Rosetta software as part of their Cyrus Bench platform. More information about Cyrus’ license arrangement with the University of Washington (acting on behalf of the Rosetta Commons) is available at this FAQ.

Janssen Research & Development LLC has licensed Rosetta and PyRosetta software from University Of Washington who manages the licensing on behalf of the Rosetta Commons. In 2024, Prof. Gray provided paid consulting services to Janssen Research & Development, LLC. and is also an unpaid member of the Executive Board of the Rosetta Commons.

Prof. Gray is an unpaid member of Board of Directors of the Open Molecular Software Foundation. The Open Molecular Software Foundation funds non-human subjects research at the Johns Hopkins University in which Prof. Gray serves as Principal Investigator (an NSF POSE award subcontract).

Prof. Gray is an inventor of the IgFold technology described in Nature Communications and the IgLM technology described in Cell Systems. Under license agreements between various companies, Johns Hopkins University and Prof. Gray may be entitled to a portion of revenue received on commercial licensing of these software packages.

Prof. Michael Tsapatsis is a non-conflicted designee to whom students, trainees, etc. can turn should they have concerns. If a group member approaches Prof. Tsapatsis, he will have confidential conversations with them about their concerns and what they think would be the preferable path forward. If requested, he will first try to mitigate between the group member and the PI and, if needed, direct the case to appropriate personnel for further consideration.

Corporate Research Sponsors and Collaborative Research

These arrangements are currently pending review by the Johns Hopkins University in accordance with its conflict-of-interest policies:

The Gray lab has received funding from the following companies:

UCB Celltech for research on antibody structure prediction with NMR data (2008-2011)

GSK Vaccines for collaborative research on antibody engineering (2019-2022)

Moderna for research collaboration on computational design of immune receptors against novel antigens (2023-2026)

AstraZeneca for research collaboration on docking and computational design of antibodies (2024-2027)

Patents (filing data - issue date)

Prof. Gray is a co-inventor on the following patent filings:

1. Computationally engineered monocolonal antibodies and antigen binding fragments specific for SARS-CoV-2 spike proteins and uses thereof; FDA, JHU, and FCCC, 2022-2023 (provisional). [Paper link]

2. Generative language models and related aspects for peptide and protein sequence design; JHU, 2022-2023 (provisional). [Paper link]